The Effects of Statins on Neurotransmission and Their Neuroprotective Role in Neurological and Psychiatric Disorders.
Michał KosowskiJoanna SmolarczykMarcin HachułaMateusz MaligłówkaMarcin BasiakGrzegorz MachnikRobert PudloBogusław OkopieńPublished in: Molecules (Basel, Switzerland) (2021)
Statins are among the most widely used drug classes in the world. Apart from their basic mechanism of action, which is lowering cholesterol levels, many pleiotropic effects have been described so far, such as anti-inflammatory and antiatherosclerotic effects. A growing number of scientific reports have proven that these drugs have a beneficial effect on the functioning of the nervous system. The first reports proving that lipid-lowering therapy can influence the development of neurological and psychiatric diseases appeared in the 1990s. Despite numerous studies about the mechanisms by which statins may affect the functioning of the central nervous system (CNS), there are still no clear data explaining this effect. Most studies have focused on the metabolic effects of this group of drugs, however authors have also described the pleiotropic effects of statins, pointing to their probable impact on the neurotransmitter system and neuroprotective effects. The aim of this paper was to review the literature describing the impacts of statins on dopamine, serotonin, acetylcholine, and glutamate neurotransmission, as well as their neuroprotective role. This paper focuses on the mechanisms by which statins affect neurotransmission, as well as on their impacts on neurological and psychiatric diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), vascular dementia (VD), stroke, and depression. The pleiotropic effects of statin usage could potentially open floodgates for research in these treatment domains, catching the attention of researchers and clinicians across the globe.
Keyphrases
- cardiovascular disease
- cerebral ischemia
- mental health
- anti inflammatory
- atrial fibrillation
- mild cognitive impairment
- blood brain barrier
- systematic review
- coronary artery disease
- adverse drug
- type diabetes
- stem cells
- palliative care
- depressive symptoms
- mesenchymal stem cells
- emergency department
- bone marrow
- physical activity
- case control
- machine learning
- metabolic syndrome
- brain injury
- big data